Utilizing our AIM™ nanotechnology platform, we create nanoparticle-based artificial Antigen Presenting Cells (aAPCs) that bypass the role of natural dendritic cells in modulating an immune response to a cancer.

Here’s a closer look at how AIM™ technology works:

Addressing Impaired Dendritic Cell Function: Natural antigen presenting cells (APCs) play a critical role in the body’s immune system as they activate and direct other immune system cells, including T cells, in orchestrated attacks against specifically targeted antigens and cells. However, under certain disease conditions, natural APCs such as dendritic cells can become impaired through pre-treatment and underlying disease.

Dendritic cells are highly specialized immune cells that, under normal conditions, act to control and direct the body’s immune system. They have the ability to educate, activate and direct other specific immune cells (T cells) to identify, engage and kill diseased cells (eg, tumor cells and virally infected cells). When patients suffer disease, their dendritic cells become dysfunctional and lose their ability to effectively control the immune system and can no longer direct an immune attack against invading pathogens and / or malignant cells.

Our proprietary AIM™ technology has been designed to drive specific immune system responses in a highly controllable and reproducible way independent of the functional effectiveness or abundance of the patient’s natural APC.

Artificial Antigen Presenting Cells: Our AIM™ platform is based on the pioneering work developing artificial Antigen Presenting Cells (aAPCs) by our scientific co-founders Mathias Oelke and Jonathan Schneck (Oelke and Schneck 2003 and 2010). These aAPCs are designed to mimic the core functions of natural Antigen Presenting Cells, such as dendritic cells by delivering two key antigen presenting cell signals: (i) an antigen-specific recognition signal delivered by an MHC molecule loaded with an antigenic peptide (Signal 1), and (ii) a co-stimulatory signal to direct action by the T cells (Signal 2).

AIM™ nanoparticles Directly Engage and Activate T Cell Function: Following antigen-specific activation by either an aAPC or a natural antigen presenting cell, T cells undergo clonal selection and become either memory cells or cytotoxic effector cells. Effector cells are activated and perform cytotoxic killing of T cells in part through the release of cytotoxic granules.

Our immunotherapies utilize aAPCs that provide a unique mechanism of action (MOA) that optimizes endogenous T cells for maximum therapeutic effect and restoration of natural immunity.


Our precision AIM™ technology forms the foundation of the development of novel immunotherapies with curative potential in cancer, autoimmune and infectious diseases, and other life-threatening conditions.

View Applications


AIM™ nanoparticles are able to precisely stimulate unparalleled levels of antigen-specific T cells for treating disease.

View Differentiation

Patents & Publications

Read foundational papers and intellectual property on our AIM™ technology.

View Publications